Mads Hald Andersen

Mads Hald Andersen

Clinical Professor

Member of:

    ORCID: 0000-0002-2914-9605

    Publication year:
    All
    1 - 25 out of 142Page size: 25
    1. 2023
    2. Published

       of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

      Hulen, T. M., Friese, C., Kristensen, N. P., Granhøj, J. S., Borch, T. H., Peeters, M. J. W., Donia, M., Andersen, Mads Hald, Hadrup, S. R., Svane, Inge Marie & Met, Özcan, 2023, In: Frontiers in Immunology. 14, 15 p., 1180997.

      Research output: Contribution to journal › Journal article › Research › peer-review

    3. Published

      An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial

      Grauslund, J. H., Holmström, M. O., Martinenaite, E., Lisle, T. L., Glöckner, H. J., Fassi, Daniel El , Klausen, U., Mortensen, R. E. J., Jørgensen, N., Kjær, L., Skov, V., Svane, Inge Marie, Hasselbalch, Hans Carl & Andersen, Mads Hald, 2023, In: Frontiers in Immunology. 14, 14 p., 1117466.

      Research output: Contribution to journal › Journal article › Research › peer-review

    4. Published

      Antibodies to calnexin and mutated calreticulin are common in human sera

      Kyllesbech, C., Trier, N. H., Mughal, F. P., Hansen, Paul Robert, Holmström, M. O., Fassi, Daniel El , Hasselbalch, H., Skov, V., Kjær, L., Andersen, Mads Hald, Ciplys, E., Slibinskas, R., Fredriksen, Jette Lautrup, Højrup, P. & Houen, G., 2023, In: Current Research in Translational Medicine. 71, 2, 103380.

      Research output: Contribution to journal › Journal article › Research › peer-review

    5. Published

      First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer

      Mørk, S. K., Kongsted, P., Westergaard, M. C. W., Albieri, B., Granhøj, J. S., Donia, M., Martinenaite, E., Holmström, M. O., Madsen, K., Kverneland, A. H., Kjeldsen, J. W., Holmstroem, R. B., Lorentzen, C. L., Nørgaard, N., Andreasen, L. V., Wood, G. K., Christensen, D., Klausen, M. S., Hadrup, S. R., thor Straten, P. & 2 others, Andersen, Mads Hald & Svane, Inge Marie, 2023, In: Frontiers in Immunology. 14, 1122977.

      Research output: Contribution to journal › Journal article › Research › peer-review

    6. Published

      Immune modulatory vaccines: time to move into infectious diseases

      Andersen, Mads Hald, 2023, In: The Lancet Microbe. 4, 1, p. e4-e5

      Research output: Contribution to journal › Comment/debate › Research › peer-review

    7. Published

      Novel immune modulatory vaccines targeting TGFβ

      Andersen, Mads Hald, 2023, In: Cellular and Molecular Immunology. 20, p. 551–553

      Research output: Contribution to journal › Comment/debate › Research › peer-review

    8. Published

      Novel immunotherapeutic combinations moving forward: the modulation of the immunosuppressive microenvironment

      Andersen, Mads Hald, 2023, In: Seminars in Immunopathology. 45, 2, p. 159-161 3 p.

      Research output: Contribution to journal › Editorial › Research › peer-review

    9. Published

      Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy

      Mortensen, R. E. J., Holmström, M. O., Lisle, T. L., Hasselby, Jane Preuss, Willemoe, G. L., Met, Özcan, Svane, Inge Marie, Johansen, Julia Sidenius, Nielsen, Dorte Lisbet, Chen, I. M. & Andersen, Mads Hald, 2023, In: Journal for ImmunoTherapy of Cancer. 11, 3

      Research output: Contribution to journal › Journal article › Research › peer-review

    10. Published

      Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms

      Hasselbalch, Hans Carl, Junker, P., Skov, V., Kjær, L., Knudsen, T. A., Larsen, Morten Kranker, Holmström, M. O., Andersen, Mads Hald, Jensen, C., Karsdal, M. A. & Willumsen, N., 2023, In: Cancers. 15, 17, 47 p., 4323.

      Research output: Contribution to journal › Review › Research › peer-review

    11. Published

      Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow

      Holmström, M. O., Andersen, M., Traynor, S., Ahmad, S. M., Lisle, T. L., Handlos Grauslund, J., Skov, V., Kjær, L., Ottesen, J. T., Gjerstorff, M. F., Hasselbalch, Hans Carl & Andersen, Mads Hald, 2023, In: Frontiers in Immunology. 14, 14 p., 1240678.

      Research output: Contribution to journal › Journal article › Research › peer-review

    12. Published

      Tumor microenvironment antigens

      Andersen, Mads Hald, 2023, In: Seminars in Immunopathology. 45, p. 253–264

      Research output: Contribution to journal › Review › Research › peer-review

    13. 2022
    14. Published

      Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV

      Klausen, U., Grauslund, J. H., Jørgensen, N. G. D., Ahmad, S. M., Jonassen, M., Weis-Banke, S. E., Martinenaite, E., Pedersen, L. B., Lisle, T. L., Gang, Anne Ortved, Enggaard, L., Hansen, M., Holmström, M. O., Met, Özcan, Svane, Inge Marie, Niemann, Carsten, Pedersen, Lars Møller & Andersen, Mads Hald, 2022, In: Frontiers in Oncology. 12, 1023015.

      Research output: Contribution to journal › Journal article › Research › peer-review

    15. Published

      Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial

      Lorentzen, C. L., Martinenaite, E., Kjeldsen, J. W., Holmstroem, R. B., Mørk, S. K., Pedersen, A. W., Ehrnrooth, E., Andersen, Mads Hald & Svane, Inge Marie, 2022, In: Frontiers in Immunology. 13, 1023023.

      Research output: Contribution to journal › Journal article › Research › peer-review

    16. Published

      Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells

      Weis-Banke, S. E., Lisle, T. L., Perez Penco, Maria, Schina, A., Hübbe, M. L., Siersbæk, M., Holmström, M. O., Jørgensen, M. A., Svane, Inge Marie, Met, Özcan, Ødum, Niels, Madsen, Daniel Hargbøl, dqp123, dqp123, Grøntved, L. & Andersen, Mads Hald, 2022, In: Journal for ImmunoTherapy of Cancer. 10, 10, e005326.

      Research output: Contribution to journal › Journal article › Research › peer-review

    17. Published

      CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment

      Lecoq, I., Kopp, K. L., Chapellier, M., Mantas, P., Martinenaite, E., Perez Penco, Maria, Rønn Olsen, L., Zocca, M. B., Wakatsuki Pedersen, A. & Andersen, Mads Hald, 2022, In: OncoImmunology. 11, 1, 2115655.

      Research output: Contribution to journal › Journal article › Research › peer-review

    18. Published

      Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine

      Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M. B., Redmond, D., Verma, S., Schad, S., George, M. M., Venkatesh, D., Ghosh, A., Hoyos, D., Molvi, Z., Kamaz, B., Marneth, A. E., Duke, W., Leventhal, M. J., Jan, M. & 23 others, Ho, V. T., Hobbs, G. S., Knudsen, T. A., Skov, V., Kjær, L., Larsen, T. S., Hansen, D. L., Lindsley, R. C., Hasselbalch, Hans Carl, Grauslund, J. H., Lisle, T. L., Met, Özcan, Wilkinson, P., Greenbaum, B., Sepulveda, M. A., Chan, T., Rampal, R., Andersen, Mads Hald, Abdel-Wahab, O., Bhardwaj, N., Wolchok, J. D., Mullally, A. & Merghoub, T., 2022, In: Science Translational Medicine. 14, 649, eaba4380.

      Research output: Contribution to journal › Journal article › Research › peer-review

    19. Published

      Immune modulatory vaccines: the safe way to inflame the tumor microenvironment & guide anti-cancer immunotherapies

      Andersen, Mads Hald, 2022, In: Immuno Oncology Insights. 3, 9, p. 401-407

      Research output: Contribution to journal › Journal article › Research › peer-review

    20. Published

      Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression

      Carnaz Simões, A. M., Holmström, M. O., Aehnlich, P., Rahbech, Anne, Radziwon-Balicka, A., Zamora, C., Wirenfeldt Klausen, T., Skov, V., Kjær, L., Ellervik, Christina, Fassi, Daniel El , Vidal, S., Hasselbalch, Hans Carl, Andersen, Mads Hald & thor Straten, P., 2022, In: Frontiers in Immunology. 13, 866610.

      Research output: Contribution to journal › Journal article › Research › peer-review

    21. Published

      Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment

      Bendtsen, S. K., Perez Penco, Maria, Hübbe, M. L., Martinenaite, E., Orebo Holmström, M., Weis-Banke, S. E., Grønne Dahlager Jørgensen, N., Jørgensen, M. A., Munir Ahmad, S., Jensen, K. M., Friese, C., Lundsager, M. T., Johansen, A. Z., Carretta, M., Ødum, Niels, Met, Özcan, Svane, Inge Marie, Madsen, Daniel Hargbøl & Andersen, Mads Hald, 2022, In: OncoImmunology. 11, 1, 2026020.

      Research output: Contribution to journal › Journal article › Research › peer-review

    22. Published

      TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer

      Perez Penco, Maria, Weis-Banke, S. E., Schina, A., Siersbæk, M., Hübbe, M. L., Jørgensen, M. A., Lecoq, I., Lara De La Torre, L., Bendtsen, S. K., Martinenaite, E., Holmström, M. O., Madsen, Daniel Hargbøl, dqp123, dqp123, Ødum, Niels, Grøntved, L. & Andersen, Mads Hald, 2022, In: Journal for ImmunoTherapy of Cancer. 10, 12, 15 p., e005491.

      Research output: Contribution to journal › Journal article › Research › peer-review

    23. Published

      Therapeutic Potential of an Immune-Modulatory Vaccination Targeting Myeloid-Derived Suppressor Cells in Myelodysplastic Syndrome

      Bentivegna, Sofia, Holmstrøm, M., Balhuizen, Alexander, Almosailleakh, M., Perez Penco, Maria, Porse, Bo Torben, Andersen, Mads Hald & Grønbæk, Kirsten, 2022, In: Blood. 140, Suppl. 1, p. 4007-4008 2 p.

      Research output: Contribution to journal › Conference abstract in journal › Research

    24. 2021
    25. Published

      Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

      Handlos Grauslund, J., Holmström, M. O., Jørgensen, N. G., Klausen, U., Weis-Banke, S. E., El Fassi, D., Schöllkopf, C., Clausen, M. B., Gjerdrum, L. M. R., Breinholt, M. F., Kjeldsen, J. W., Hansen, M., Koschmieder, S., Chatain, N., Novotny, G. W., Petersen, J., Kjær, L., Skov, V., Met, Ö., Svane, I. M. & 2 others, Hasselbalch, Hans Carl & Andersen, Mads Hald, 26 Feb 2021, In: Frontiers in Oncology. 11, 17 p., 637420.

      Research output: Contribution to journal › Journal article › Research › peer-review

    26. Published

      Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner

      Holmström, M. O., Mortensen, R. E. J., Pavlidis, A. M., Martinenaite, E., Weis-Banke, S. E., Aaboe-Jørgensen, M., Bendtsen, S. K., Met, Özcan, Pedersen, A. W., Donia, M., Svane, Inge Marie & Andersen, Mads Hald, Feb 2021, In: Cellular and Molecular Immunology. 18, 2, p. 415-426 12 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    27. Published

      A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

      Kjeldsen, J. W., Lorentzen, C. L., Martinenaite, E., Ellebaek, E., dqp123, dqp123, Holmstroem, R. B., Klausen, T. W., Madsen, C. O., Ahmed, S. M., Weis-Banke, S. E., Holmström, M. O., Hendel, Helle Westergren, Ehrnrooth, E., Zocca, M. B., Pedersen, A. W., Andersen, Mads Hald & Svane, Inge Marie, 2021, In: Nature Medicine. 27, p. pages2212–2223

      Research output: Contribution to journal › Journal article › Research › peer-review

    28. Published

      An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma

      Klausen, U., Grønne Dahlager Jørgensen, N., Grauslund, J. H., Munir Ahmad, S., Gang, Anne Ortved, Martinenaite, E., Weis-Banke, S. E., Breinholt, M. F., Novotny, G. W., Kjeldsen, J. W., Orebo Holmström, M., Pedersen, L. B., Poulsen, C. B., Hansen, P. B., Met, Özcan, Svane, Inge Marie, Niemann, Carsten, Pedersen, Lars Møller & Andersen, Mads Hald, 2021, In: OncoImmunology. 10, 1, 1975889.

      Research output: Contribution to journal › Journal article › Research › peer-review

    Previous 1 2 3 4 5 6 Next

    ID: 13571778